Patrick J. Heron, Director at Arcutis Biotherapeutics, Inc. (ARQT), bought 8,674 shares at $13.76 ($119K) on 2025-05-14, disclosed to the SEC on 2025-05-15.
Open-market purchase of $119k ARQT by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade C.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $13.76 | 2,374 | $33K | 27.4% |
| 2 | $13.76 | 6,300 | $87K | 72.6% |
| Total | $13.76 avg | 8,674 | $119K | 100% |
| Filing → |
| ARQT | BUY | 2025-06-06 | $30K | — | Filing → |
| ARQT | BUY | 2025-05-23 | $69K | — | Filing → |
| ARQT | BUY | 2025-05-19 | $34K | — | Filing → |